Skip to main content
. 2017 Feb 23;8(17):28696–28710. doi: 10.18632/oncotarget.15645

Figure 2. Effects of genetic (shRNA) downregulation of CDK9.

Figure 2

(A) The down-regulated CDK9 expression in SKGT4 cells by stable shCDK9 was confirmed by western blot (top panel). Effects of stable shCDK9 on cell proliferation in SKGT4. Cell proliferation was measured by MTS assay using the CellTiter Aqueous One Solution Cell Proliferation Assay kit (three separate experiments). (B) Effects of stable shCDK9 on the apoptosis of SKGT4 cells (three separate experiments). Cells stained with propidium iodide alone were considered necrotic, whereas cells stained with Annexin V with and without staining with propidium iodide were considered apoptotic. (C). Effects of stable shCDK9 on cell cycle stages in SKGT4 cells (three separate experiments) showing G1 arrest of shCDK9 SKGT4 vs. control. (D) Representative photograph of tumor xenografts and (E) the volume (means ± SE) of tumor xenografts at end of the experiment with stable shCDK9 and control SKGT4 cells. *represents p-value <0.05 compared to untreated controls. →: xenograft of shCDK9. ►: xenograft of controls. (F) Western blot analysis of MCL-1, c-MYC expression and phosphorylation of RNA pol II in stable SKGT-4-shCDK9 and control cells. (G) Western blot analysis of MCL-1 and c-MYC expression and phosphorylation of RNA Pol II after transient shCDK9. Cell lysate from cells infected with lenti-shCDK9 for 72 hours were analyzed by western blot with antibodies against to MCL-1, c-MYC or phosphorylated RNA pol II at S2 site (two separate experiments).